Organization
Cassava Sciences
8 clinical trials
Clinical trial
An Open-Label Extension of the PTI-125-04 Study Evaluating the Safety and Long-Term Treatment of Simufilam in Mild-to-Moderate Alzheimer's Disease PatientsStatus: Active (not recruiting), Estimated PCD: 2025-10-29
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease PatientsStatus: Completed, Estimated PCD: 2023-11-09
Clinical trial
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2024-03-27
Clinical trial
A Four-way Crossover Food Effect and Bioequivalence Pharmacokinetic Study of Simufilam in Healthy VolunteersStatus: Completed, Estimated PCD: 2021-05-11
Clinical trial
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic FunctionStatus: Not yet recruiting, Estimated PCD: 2025-01-28
Clinical trial
An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer's DiseaseStatus: , Estimated PCD: 2026-07-15